Neptune Obtains Allowance of Patent Specific to Krill Oil and Announces Management Reorganization

Neptune Obtains Allowance of Patent Specific to Krill Oil and Announces
Management Reorganization

LAVAL, Quebec, Jan. 24, 2013 (GLOBE NEWSWIRE) -- Neptune Technologies &
Bioressources Inc. ("Neptune") (Nasdaq:NEPT ) (TSX:NTB) announces that the
U.S. Patent & Trademark Office (the "USPTO") has allowed a second continuation
patent application, application number 13/545,830, which claims the benefit of
prior Neptune U.S. Patents No. 8,030,348 ("the '348 Patent") and 8,278,351
("the '351 Patent").

This second continuation application contains only a single claim, which is
directed to a capsule comprising an Antarctic krill oil extract comprising a
phospholipid suitable for human consumption. This claim covers most, if not
all, krill oil products presently sold in the U.S. market.

This second continuation application, which was filed less than six (6) months
ago, was allowed by the USPTO after a thorough examination. During
prosecution, Neptune provided the USPTO with all prior art references and
other materials, including all the documents referred to in all of the
re-examination requests filed by Aker Biomarine ASA ("Aker") directed to the
'348 and '351 Patents, as well as all the documents relating to the
oppositions currently underway on related Neptune patents in Europe and
Australia.

Tina Sampalis, M.D., Ph.D., Chief Global Strategy Officer of Neptune, stated:
"This single claim patent, which will be granted shortly, not only covers
Neptune's krill oil products but also the krill oil products of our
competitors. The fact that the USPTO has allowed a second continuation patent
is an indication to us that all the prior art, experimental evidence, and
arguments submitted by Aker in the different re-examination and opposition
proceedings relating to the other Neptune patents have no merit. It is
becoming more and more difficult for our competitors to downplay or disregard
Neptune's patent estate."

"We are continuously building and strengthening our intellectual property
assets. Despite the tragic events suffered by Neptune on November 8, 2012, we
are committed to maintaining our pioneering role in the krill oil industry and
we intend to fully enforce our patents against anyone who infringes," she
added.

Management Reorganization

Neptune also announces that, effective January 23, 2013, Henri Harland,
President and Chief Executive Officer of Neptune, will cumulate for an interim
period of time, during the implementation of Neptune's plan to resume
production, the functions and responsibilities held previously by Michel
Chartrand, as Chief Operating Officer, who will continue to hold office as
member of the Board of Director. "Michel and I came to the conclusion that
until Neptune resumes operations at its production plant; it was in Neptune's
best interest to abolish the office of Chief Operating Officer for an interim
period of time. We believe that Michel will better serve Neptune's interests
by focusing on his responsibilities as Director of the company during his
mandate," said Henri Harland.

"On behalf of the Neptune family, I want to thank Michel for his relentless
efforts and devotion to Neptune's employees and families most affected by the
recent tragic events," he added.

As part of the management reorganizational efforts announced previously by
Neptune in its action plan going forward, Neptune also wishes to confirm that
its directors, senior management and employees have accepted salary reductions
of 20% for an interim period during the implementation of Neptune's plan to
resume production.

About Neptune Technologies & Bioressources Inc.

Neptune is a biotechnology company engaged primarily in the development and
commercialization of marine-derived omega-3 polyunsaturated fatty acids, or
PUFAs. Neptune has a patented process of extracting oils from Antarctic krill,
which omega-3 PUFAs are then principally sold as bulk oil to Neptune's
distributors who commercialize them under their private label primarily in the
U.S., European and Asian neutraceutical markets. Neptune's lead products,
Neptune Krill Oil (NKO®) and ECOKRILL Oil (EKO™), generally come in capsule
form and serve as a dietary supplement to consumers.

Through its subsidiaries Acasti Pharma Inc. ("Acasti") (TSX-V:APO)
(Nasdaq:ACST) and NeuroBioPharm Inc. ("NeuroBioPharm"), in which Neptune
respectively holds 57% and 96% of the voting rights, Neptune is also pursuing
opportunities in the medical food and prescription drug markets. Acasti and
NeuroBioPharm respectively focus on the research and development of safe and
therapeutically effective compounds for highly prevalent atherosclerotic
conditions, such as cardiometabolic disorders and cardiovascular diseases, and
for neurodegenerative and inflammation related conditions. Acasti's lead
prescription drug candidate is CaPre®, a purified high omega-3 phospholipid
concentrate derived from Neptune krill oil being developed to address the
prevention and treatment of cardiometabolic disorders, including
hypertriglyceridemia, which is characterized by abnormally high levels of
triglycerides.

Forward Looking Statements

Certain statements included in this press release may be considered
forward-looking information within the meaning of Canadian securities laws and
forward-looking statements within the meaning of U.S. federal securities laws,
both of which we refer to as forward-looking statements. Such statements
involve known and unknown risks, uncertainties and other factors that may
cause results, performance or achievements to be materially different from
those implied by such statements, and therefore these statements should not be
read as guarantees of future performance or results. All forward-looking
statements are based on Neptune's current beliefs as well as assumptions made
by and information currently available to Neptune and relate to, among other
things, Neptune's strategy, strategic goals, research and development
activities, research and clinical testing outcome, future operations, future
financial position, future revenues/results, projected costs, prospects and
plans and objectives of management.

Readers are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date of this press release. Due to
risks and uncertainties, including the risks and uncertainties identified by
Neptune in its amended and restated annual information form dated September
11, 2012, in its press release announcing an action plan to resume operations
and supply customers dated November 26, 2012 and in its other public
securities filings available at www.sedar.com and www.sec.gov/edgar.shtml,
actual events may differ materially from current expectations. Except as
required by law, Neptune disclaims any intention or obligation to update or
revise any forward-looking statements.

CONTACT: Neptune Contact:
         Neptune Technologies & Bioressources Inc.
         Andre Godin, CFO
         +1.450.687.2262
         a.godin@neptunebiotech.com
         www.neptunebiotech.com
        
         Howard Group Contact:
         Dave Burwell
         (888) 221-0915
         dave@howardgroupinc.com
         www.howardgroupinc.com
 
Press spacebar to pause and continue. Press esc to stop.